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Summary 
Background:  
Standard treatment for deep vein thrombosis includes anticoagulation and compression therapy. 
Accelerated lysis of venous thrombus by additional catheter-directed thrombolysis is suggested to 
reduce the development of postthrombotic syndrome. Large scale randomized controlled trials with 
long-term follow-up are needed to evaluate additional thrombolysis compared with standard 
treatment alone. Traditionally clinical trials on deep vein thrombosis have not employed functional 
outcomes with assessment of postthrombotic syndrome and quality of life, and this should be 
included. Routine diagnostic imaging with ultrasound for detection of acute deep vein thrombosis is 
not always feasible. 
Aims: 
The overall objective was to evaluate and improve diagnostic imaging and therapy of deep vein 
thrombosis of the lower limb with focus on catheter-directed thrombolysis and MRI. The first aim 
was to design and implement a well designed trial for the evaluation of additional catheter-directed 
thrombolysis. The second aim was translation and psychometric evaluation with assessment of data 
quality, reliability and validity, of a disease-specific questionnaire for patient reported quality of life 
following venous thrombosis of the lower limb. Final aim was to compare balanced MRI with 
contrast-enhanced MRI in visualisation of the deep veins and detection of acute deep vein 
thrombosis with ultrasound as reference method. 
Materials and methods: 
In the CaVenT Study a total of 200 patients with acute iliofemoral deep vein thrombosis will be 
recruited to detect a clinically relevant reduction in postthrombotic syndrome from 25 % to 10 % 
after 2 years. The patients are randomized to receive additional thrombolysis or standard treatment 
alone. The first 118 recruited patients were included in the analyses on short-term patency. Non-
invasive assessment of veins, clinical assessment of postthrombotic syndrome, and patient-reported 
outcome on quality of life were performed after 6 and 24 months. The quality of life validation study 
was performed on a subset of 74 patients in the CaVenT Study using a novel Norwegian translation of 
the VEINES-QOL/Sym questionnaire. Balanced and contrast enhanced MRI were performed in 15 
healthy volunteers and 6 patients with proximal deep vein thrombosis verified with ultrasound. 
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Results: 
 A psychometric evaluation of the Norwegian version of the VEINES-QOL/Sym questionnaire 
indicated satisfactory data quality, item-total correlations, internal consistency, test-retest reliability, 
and construct validity. Additional catheter-directed thrombolysis resulted in effective lysis in the 
great majority of patients. After 6 months venous patency was improved (64.0% vs. 35.8%) and 
venous obstruction was reduced (20.0% vs. 49.1%) when comparing additional thrombolysis with 
standard treatment alone. Venous incompetence was detected in the majority of patients, and did 
not differ between the two groups. Balanced and contrast-enhanced MRI techniques were 
comparable in visualizing the deep veins of the lower limb. Diagnostic properties and inter-observer 
reliability of both MRI sequences were good for proximal and poor for distal deep vein thrombosis.  
Conclusions: 
The CaVenT study is a considerable contribution towards a more evidence-based practice in the 
treatment of deep vein thrombosis, and future long-term results may lead to a modification of 
clinical guidelines. The psychometric properties of the Norwegian version of the VEINES-QOL/Sym 
questionnaire support its use in the evaluation of patient outcomes and burden of illness in clinical 
studies on deep vein thrombosis. Additional catheter-directed thrombolysis improved short-term 
venous patency compared to anticoagulation and compression therapy only. Both balanced and 
contrast-enhanced MRI may be used for the detection of proximal deep vein thrombosis in patients 
where ultrasound is not feasible. 
  
13 
 
Abbreviations 
 
2D/3D  two/three dimensional (MRI) 
ACCP  American College of Chest Physicians 
aPTT  activated partial thromboplastin time 
ARR  absolute risk reduction 
CDT  catheter-directed thrombolysis 
CI  confidence interval 
CNR  contrast-to-noise ratio 
DVT  deep vein thrombosis 
ECS  elastic compression stockings 
FISP  fast imaging with steady-state precession (MRI) 
FVL  factor V Leiden mutation 
iv  intravenous 
ISTH  International Society of Thrombosis and Haemostasis 
LMWH  low molecular weight heparin 
MRDTI  magnetic resonance direct thrombus imaging 
MRI  magnetic resonance imaging 
NA  not applicable/not available 
PE  pulmonary embolism 
PTS  postthrombotic syndrome 
QOL  health-related quality of life 
RCT  randomized controlled trial 
RR  relative risk 
sc  subcutaneous 
SD  standard deviation 
SR  systematic review 
TOF  time-of-flight (MRI) 
US  ultrasound 
VCI  vena cava inferior  
VESPA  venous enhanced subtracted peak arterial (MRI) 
VTE  venous thromboembolism 
  
14 
 
  
15 
 
List of papers 
The thesis is based on the following papers, referred to in the text by their Roman numerals. 
 
Paper I 
Enden T, Sandvik L, Kløw NE, Hafsahl G, Holme PA, Holmen PO, Ghanima W, Njaastad AM, Sandbæk 
G, Slagsvold CE, and Sandset PM. Catheter-directed Venous Thrombolysis in acute iliofemoral vein 
thrombosis - the CaVenT Study: Rationale and design of a multicenter, randomized, controlled, 
clinical trial (NCT00251771). American Heart Journal 2007;154:808-14. 
Paper II 
Enden T, Garratt AM, Kløw NE, and Sandset PM. Assessing burden of illness following acute deep vein 
thrombosis: data quality, reliability and validity of the Norwegian version of VEINES-QOL/Sym, a 
disease-specific questionnaire. Scandinavian Journal of Caring Sciences 2009;23:369-74 
Paper III 
Enden T, Sandvik L, Kløw NE, Hafsahl G, Holme PA, Holmen PO, Ghanima W, Njaastad AM, Sandbæk 
G, Slagsvold CE, and Sandset PM. Catheter-directed thrombolysis versus anticoagulant therapy alone 
in deep vein thrombosis: Results of an open randomized, controlled trial reporting on short term 
patency. Journal of Thrombosis and Haemostasis 2009;7:1268-75. 
Paper IV 
Enden T, Storaas T, Negaard A, Haig Y, Sandvik L, Gjesdal KI, Sandset PM, Kløw NE. Visualisation of 
the deep veins and detection of deep vein thrombosis with balanced TFE and contrast-enhanced T1 
FFE using a blood pool agent. Submitted JMRI. 
 
  
16 
 
Additional publications related to the CaVenT Study 
(Included for information only). 
1. Enden T, Sandset PM. Lancet protocol Reviews, protocol 07PRT/295: Catheter-directed 
Venous Thrombolysis in acute iliofemoral vein thrombosis — the CaVenT study. 
http://www.thelancet.com/journals/lancet/misc/protocol/07PRT-295   
2. Schulman S. Getting intimate with the venous thrombus (editorial) . Journal of Thrombosis 
and Haemostasis 2009;7:1266-7. 
3. Enden T, Kløw NE, Sandset PM. Kateterbasert trombolytisk behandling ved akutt dyp 
venetrombose (commentary). (Catheter-directed thrombolysis in acute deep venous 
thrombosis). Tidsskrift for den Norske Lægeforening 2006; 126:1765 
4. Enden T, Kløw NE, Sandset PM, Aas E. Cost-effectiveness of catheter-directed thrombolysis in 
iliofemoral deep vein thrombosis; a model based on the CaVenT study (RCT) (abstract). 
Health Technology Assessment international, Barcelona 2007 June. 
  
17 
 
1. Introduction 
Deep vein thrombosis (DVT) of the lower limb is a common disease associated with substantial 
morbidity (1). In clinical practice acute DVT is routinely verified by diagnostic imaging using 
ultrasound, but in some patients ultrasound may not be feasible. Standard treatment of DVT includes 
anticoagulation (AC) for prevention of thrombus formation and compression therapy for reducing 
postthrombotic syndrome (PTS). Still, following adequate standard therapy a number of patients 
with proximal DVT will develop PTS with a chronically reduced functional outcome. To improve the 
clinical outcome for patients with DVT there is continued need for better diagnostic and therapeutic 
approaches, and the work of this thesis has examined the role of diagnostic MRI (magnetic resonance 
imaging) and thrombolytic therapy. 
1.1 Deep vein thrombosis of the lower limb 
DVT is acute abnormal clotting in deep veins hindering normal flow of venous blood. This may take 
place when at least one of the three following occurs; venous stasis, vessel wall injury and/or 
hypercoagulability, known as Virchow’s triad since 1856 (2). The initial thrombus formation usually 
takes place in the paired calf veins, and if not recognized and treated may result in continuous 
clotting and more proximal extension of the clot (1).  When attending medical help, 85% have 
developed proximal DVT affecting the popliteal or more proximal veins (3). Thrombotic material may 
embolize and finally lodge in the pulmonary arterial circulation causing pulmonary embolism (PE) in 
up to 50 % of patients with proximal DVT (4).  DVT of the lower limb may cause substantial acute and 
chronic morbidity, and even death in cases of severe PE.  
Estimated incidence of acute DVT is approximately 1/1000/year (5). Several risk factors for venous 
thromboembolism (VTE) have been identified and can be classified as acquired or inherited as 
summarized in table 1. From this follows that patients suffering from DVT are encountered in a wide 
range of medical specialties including oncology, haematology, obstetrics and gynaecology, 
orthopaedics, surgery, and emergency medicine. Approximately 40% have idiopathic VTE with no 
identified risk factor (5). 
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Table 1 Risk factors for venous thromboembolism, adapted from (6;7) 
Acquired risk factors 
Age (especially >75 years)  
Surgery Infection 
Trauma Heart failure 
Malignancy Respiratory failure, chronic obstructive lung disease 
Cancer therapy (hormonal chemotherapy 
or radiotherapy) 
Estrogen-containing oral contraception, or hormone replacement 
therapy or selective estrogen receptor modulator therapy 
Prolonged immobility, paresis Nephrotic syndrome 
Previous venous thromboembolism Myeloproliferative disorders 
Increased age (especially > 75 yr) Obesity 
Pregnancy and postpartum status Smoking 
Inflammatory bowel disease Varicose veins 
Travel (long haul flights) Central venous catheterization 
Antiphospholipid antibodies  
Inherited risk factors 
1st degree relative with venous thromboembolism 
Thrombophilia: Factor V Leiden mutation 
 Prothrombin gene (G20210A) mutation 
 Antithrombin deficiency 
 Protein C deficiency 
 Protein S deficiency 
 
1.1.1 Chronic postthrombotic complications 
Chronic changes of the leg following proximal DVT include swelling, pain, discomfort, deterioration of 
skin and possibly ulcers. This is recognized as the postthrombotic syndrome (PTS). The symptoms are 
typically most pronounced at the end of the day, and aggravated by standing and walking. PTS 
probably evolves from venous obstruction as a result of persistent postthrombotic changes and/or 
venous incompetence caused by inflammatory destruction of venous valves in response to acute 
thrombotic occlusion (8). Both obstruction and incompetence may lead to chronic venous 
hypertension, resulting in edema, pigmentation, fibrosis, and ulceration. However, the 
pathophysiologic mechanisms remain unclear (9). PTS develops in approximately every fourth patient 
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following adequate standard therapy (10;11). In addition to significant morbidity PTS is associated 
with reduced quality of life (QOL) and substantial costs (12-14). 
1.2 Diagnostic imaging of deep vein thrombosis 
The typical symptoms of DVT are acute onset of pain, swelling, and erythema of the lower limb, but 
the clinical presentation may be highly variable and misleading. Estimation of individual clinical 
probability of DVT using a prediction rule like the Wells’ score (15), improves diagnostic accuracy. 
Combined with the high specificity and negative predictive value of D-dimer, a specific product of 
fibrin degradation, diagnostic imaging is not necessary in patients with low clinical probability and 
negative D-dimer (16). In all cases of high clinical probability, diagnostic imaging should be performed 
to objectively secure the diagnosis. In clinical practice compression ultrasound is the method of 
choice, possibly combined with Doppler (17;18). A meta-analysis of the diagnostic accuracy of 
ultrasound for symptomatic DVT included 100 cohorts where ultrasound was compared to 
venography, the former reference method (table 2) (17). Overall sensitivity was at least 94% for 
proximal DVT. Sensitivity for distal DVT was improved by using Doppler, while specificity was at least 
94% independent of whether compression technique only and/or Doppler were used.  
 
Table 2 Sensitivity and specificity of ultrasound in patients with suspected DVT of the lower limb (17) 
Ultrasound technique 
Sensitivity 
Specificity 
Proximal DVT Distal DVT 
Overall 94.2% 63.5% 93.8% 
Duplex* 96.5% 71.2% 94.0% 
Triplex** 96.4% 75.2% 94.3% 
Compression only 93.8% 56.8% 97.8% 
* Combined compression and color Doppler ultrasound 
** Combined compression, color Doppler and continuous wave Doppler ultrasound 
 
In some patients ultrasound is not feasible if obesity, severe oedema, plaster casts, wound dressings 
etc cause inadequate penetration of the ultrasound. The method also has limitations in diagnosing 
acute on chronic DVT and asymptomatic DVT (19;20). Finally, it may not be possible to completely 
visualise the iliac veins with any ultrasound technique because of their deep location in the pelvis 
and overlying disturbing bowel gas (21). Alternative, easily accessible imaging is venography and CT 
(computer tomography) when ultrasound is inconclusive. However, these examinations include 
radiation and injection of intravenous iodine-based contrast agent, causing discomfort to the patient 
and may carry adverse effects such as kidney failure, anaphylactoid reactions and increased risk for 
radiation induced malignancy. CT venography of the lower limb has so far not been shown to hold a 
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position in the primary diagnostic work up for acute DVT, but may be preferred for, e.g., intensive 
care patients (22). In patients with suspected PE, however, a CT pulmonary angiography should be 
carried out (4;23), and an immediately following (“follow-on”) CT venography utilizing the already 
given contrast agent, may give additional information in this patient group (24). 
Regarding visualisation of pelvic structures, it is known from general radiology that CT and MRI are 
superior to ultrasound. In addition, both methods have overall high technical efficacy, visualise deep 
structures practically independent of patients’ constitution, and allow visualisation of secondary 
signs of acute thrombosis and ancillary findings, e.g., peri-venous inflammation, vein abnormalities, 
and other structural changes (tumours, strictures, etc.).  
1.2.1 MRI 
The search for an ideal imaging modality along with the fast developing and highly advanced MRI 
technology, have led to a number of MRI techniques for detection of acute DVT. Overall the results 
are promising, but implication in clinical practice has been slow. Reasons for this may be various, 
including high costs, restricted availability, long acquisition times, large variation in techniques 
developed and evaluated during the last two decades, and no large scale studies for confirmation of 
preliminary reports. 
Studies on MRI detection of acute DVT report sensitivities of 87-100% and specificities of 82-100%, 
with results improving during the last decade (table 3). MRI venography has been performed with 
and without use of contrast agent, but also imaging of the thrombus itself has been demonstrated 
with a so-called direct thrombus imaging technique (MRDTI) (25).  A  systematic review (SR) with 
meta-analysis of 14 studies on the accuracy of MRI in diagnosis of suspected DVT showed similar 
results, and so far no particular MRI technique has proven superior (26). The authors concluded that 
the “meta-analysis suggests that MRI has similar diagnostic accuracy to ultrasound, although this is 
based upon a relatively small number of heterogeneous studies. Given the cost and inconvenience of 
performing MRI, it is clear that MRI will not replace ultrasound as a first-line investigation for DVT. 
MRI may offer an alternative for patients in whom ultrasound is inappropriate, not feasible, or yields 
inconclusive results”. Part of the significant heterogeneity in the SR may be explained by the varying 
MRI methods, but the results should also be interpreted with caution because of high prevalence of 
DVT in several of the studies. In populations with suspected DVT undergoing diagnostic imaging, DVT 
is found in 20-25% (18), and a higher prevalence may indicate selection bias among recruited 
patients. 
21 
 
Up to recently the use of gadolinium based MRI contrast has been considered safe, however, it is 
now clear that in some cases of severe kidney failure, there is a risk of developing the chronic and 
non-curable condition nephrogenic systemic fibrosis (27). Whether this applies to the new 
“generation” of so called blood pool agents, is not unlikely. Blood pool agents has the advantage of 
remaining intravascular long enough to allow high resolution imaging up to 30-60 min after iv 
administration. With regards to rare and potentially serious complications and costs, a method not 
relying on MRI contrast is therefore beneficial. 
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1.3 Testing efficacy of diagnostic imaging 
In studies of diagnostic imaging the efficacy of the examination can be evaluated on different levels, 
and a hierarchical model of 6 levels has been suggested (42), as summarised in table 4 (43). A novel 
method of diagnostic imaging should initially be evaluated on level 1, followed by level 2. The 
measures on level 1 are mainly technical parameters allowing comparison of one image system with 
another based on physical attributes. In addition, assessment of inter-observer variation is included 
on this level. The measures of analyses on level 2 express diagnostic accuracy, and depending on the 
clinical setting various measures can be used (42;44;45). 
Table 4 Levels of efficacy and typical measures of analyses in diagnostic imaging thornbury (42;43) 
Level of efficacy Typical measures of analyses Comment 
1  Technical, pre-clinical Resolution, gray scale range, sharpness, signal-to-
noise ratio, contrast-to-noise ratio, inter observer 
variation  
Image quality 
2 Clinical, diagnostic 
accuracy 
Abnormal vs. normal findings, percentage correct 
diagnoses, sensitivity and specificity in defined 
clinical setting, positive and negative predictive 
value, area under the receiver-operation–
characteristic (ROC) curve 
Compare to 
 reference method 
3 Clinical, diagnostic-thinking Impact on and change in diagnostic algorithm  
4 Clinical, therapeutic Impact on and change in therapeutic decisions  
5 Patient-outcome Mortality, morbidity, patient reported measures,  
QOL 
Multicenter, 
controlled trials 
6 Societal Cost-effectiveness 
Implementation studies 
Societal viewpoint 
 
Previous reports indicating suboptimal quality of methods in studies of diagnostic accuracy led to the 
international STARD (Standards for Reporting of Diagnostic Accuracy) initiative and checklist (46), 
with the objective to improve “accuracy and completeness of reporting of studies of diagnostic 
accuracy, to allow readers to assess the potential for bias in the study (internal validity) and to 
evaluate its generalizability (external validity)” (www.stard-statement.org). 
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1.4 Standard treatment for deep vein thrombosis 
Standard treatment for DVT is found in continually updated international guidelines (47). In 
summary, anticoagulation (AC) and compression therapy should be given to patients with verified 
acute DVT (Grade 1A recommendations1
1.4.1 Anticoagulation 
).  
AC is given initially as heparin followed by oral warfarin for at least 6 months for iliofemoral DVT (47). 
AC prevents further formation of venous thrombus, recurrent thrombus formation and thrombus 
embolization (1). Consequently both morbidity and mortality are reduced. Adequate AC may play a 
role in reducing risk of PTS development (49). Following a first time VTE, all patients are at risk of 
experiencing recurrent thrombosis. As several known and unknown factors influence recurrence, the 
optimal duration of AC remains uncertain in several subgroups of patients (50). Patients with 
idiopathic thrombosis or a persistent risk factor experience recurrent VTE in at least 10% per year, 
compared to 	
patients with transient risk factor(s) (1). The duration of AC has to be 
decided by balancing the individual patient’s risk of recurrent VTE with and without treatment, and 
the risk of AC-related bleeding (50). A SR of 2006 estimated frequency of recurrent VTE per 100 
patient years to be 4.9 (95% CI 3.5-6.2) when treated with AC for 4-12 months and 0.7 (95% CI 0.3-1-
1) on continuous AC (51). Corresponding numbers for estimated frequency of bleeding were 0.7 (95% 
CI 0.4–1.0) and 1.6 (95% CI 0.5–2.7), respectively. 
1.4.2 Elastic compression stockings 
Elastic compression stockings (ECS) are recommended for 24 months following a proximal DVT, as 
this has been shown to reduce the risk of PTS with approximately 50% in 2 open randomized, 
controlled trials (RCT), see table 5 (10;11). The stockings should be knee-high, worn daily whenever 
out of bed, and execute an external pressure of approximately 30 mmHg (class II ECS). The external 
pressure from ECS reduces venous hypertension and reflux (10). 
  
                                                          
1 Grade 1A recommendations: “Strong recommendation, high-quality evidence. Desirable effects 
clearly outweigh undesirable effects. Consistent evidence from RCTs without important limitations … 
Recommendations can apply to most patients in most circumstances; further research is very unlikely 
to change our confidence in the estimate of effect” (1). 
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Table 5 ECS and frequency of PTS at 24 months following a proximal DVT of the lower limb  
Year 1st author Group PTS No PTS Duration of follow-up 
1997 Brandjes (11)   ECS 30 (31%) 66 (69%) Median 76 months 
Range 60-96 months   Control 69 (70%) 29 (30%) 
2004 Prandoni (10) ECS 23 (26%) 67 (74%) Mean 	
 
Range 6-60 months   Control 44 (49%) 46 (51%) 
 
1.5 Additional thrombolytic therapy 
Table 5 shows that when applying the recommended standard therapy, still one in four patients 
suffering a proximal DVT is at risk of developing PTS (10;11). Accelerating the removal of venous 
thrombus by thrombolytic agents has been suggested to prevent the development of PTS. The 
current knowledge regarding the effects of additional venous thrombolysis is summarised in a 
Cochrane review from 2004 (52). Among the 12 studies included, only one made use of catheter-
directed technique. In spite of being more effective than endogenous fibrinolysis in achieving 
thrombolysis (figure 1), documentation on clinically relevant outcomes is very sparse with results 
suggesting a positive effect with some reduction in PTS (figure 2). The conclusions of the Cochrane 
review were “Thrombolysis appears to offer advantages in terms of reducing PTS and maintaining 
venous patency after DVT”, and “optimum drug, dose and route of administration have yet to be 
determined”.  
Additional thrombolysis implies an additional risk of bleeding. Following thrombolysis there were 
significantly more bleeding complications with early clinically relevant bleeding (cerebral bleeding 
excluded) in 44/440 in thrombolysis group and 18/228 of controls, corresponding to a pooled relative 
risk (RR) of 1.73 (95% CI 1.04-2.88) (52). Early cerebral bleeding was reported in 2/459 in 
thrombolysis group and 0/242 of controls, and pooled RR was 1.70 (95% CI 0.21-13.70). The authors 
stated that “the incidence of bleeding appears to have reduced over time with the introduction of 
stricter selection criteria”.  
Finally, regarding systemic thrombolysis the recent American College of Chest Physicians’ (ACCP) 
guidelines suggest that “In selected patients with extensive proximal DVT (…) who have a low risk of 
bleeding, …may be used to reduce acute symptoms and postthrombotic morbidity if catheter-
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directed thrombolysis (CDT) is not available” (Grade 2C recommendations 2
 
) (47). Systemic 
thrombolysis is in other words second to CDT due to unacceptably high risk of bleeding. 
Figure 1 Complete clot lysis; meta-analysis of thrombolysis versus standard anticoagulation alone on 
(52)3
  
 
 
                                                          
2 Grade 2C recommendations: “Weak recommendation, low or very low-quality evidence. Desirable 
effects closely balanced with undesirable… Evidence for at least 1 critical outcome from observation 
studies, case series, or RCTs with serious flaws… Other alternatives may be equally reasonable, 
higher-quality research is likely to have important impact on our confidence in the estimate of effect 
an may…change the estimate”(1). 
3 Figure 1 has been modified by TE as the terms “Favours control” and “Favours treatment” were 
incorrectly interchanged in the figure compared to the results presented in the text of the Cochrane 
report. The author L. Watson has been informed about this error, but hitherto this has not been 
corrected in an update on their report. 
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Figure 2 Postthrombotic syndrome; meta-analysis of thrombolysis versus standard anticoagulation 
alone (52) 
 
 
1.5.1 Catheter-directed thrombolysis 
Using minimal-invasive percutaneous vascular technique the thrombolytic agent is delivered as a 
continuous low-dose infusion through a catheter directly into the thrombotic segments.  A potential 
benefit of this technique is that systemic effects are minimised and frequency of bleeding is reduced. 
In an American national multicenter registry study with 287 patients receiving additional CDT, 
effective thrombolysis was achieved in approximately 80% (53). Major bleeding complications 
occurred in 11%, including 1 fatal intracranial haemorrhage. However, long-term follow up is scarce, 
and properly designed controlled trials are lacking (14;54). So far only one small RCT of 35 patients 
randomized to receive either additional CDT or AC alone has been reported (55). The results from 6 
months follow-up showed improved patency rates following CDT; 13/18 vs 2/17, p<0.001. No results 
on late follow-up have been published. 
Based on this limited documentation the ACCP changed their recommendations in Evidence-Based 
Clinical Practice Guidelines (8th Edition) regarding CDT for DVT from “We recommend against the 
routine use of CDT (Grade 1C recommendation4
                                                          
4 Grade 1C recommendations: Methodological strength of supporting evidence from observational 
studies. Implicate “intermediate–strength recommendation; may change when stronger evidence is 
available” (2). 
)” and “ We suggest that this treatment should be 
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confined to selected patients such as those requiring limb salvage (Grade 2C recommendation5)” in 
2004 (57) to “In selected patients with extensive acute proximal DVT (iliofemoral DVT, symptoms for 
<14 days, good functional status, life expectancy of >1 year) who have a low risk of bleeding, we 
suggest that CDT may be used to reduce acute symptoms and postthrombotic morbidity if 
appropriate expertise and resources are available (Grade 2B recommendation6
With the CDT procedure a persisting venous stenosis following successful thrombolysis may be 
corrected with angioplasty and possibly stent before removing the catheter. Likewise, it is possible to 
identify and at the same time treat underlying vein abnormalities disposing for thrombus formation. 
Most commonly found is the iliac vein compression syndrome (also called May Thurner syndrome) 
which may be found in up to 50% of patients with left sided iliac DVT. In these patients chronic 
pulsating pressure from the right iliac artery riding across the left iliac vein reduces venous flow and 
damages vessel wall, eventually inducing a left-sided iliofemoral DVT (58). 
)” in 2008 (47). 
1.5.2 Thrombolytic agents 
All thrombolytic agents work by inducing the conversion of plasminogen to plasmin, which again 
disintegrates the fibrin mesh of the clot resulting in lysis of thrombus material. All agents may cause 
bleeding. The previously reported thrombolytic agents in VTE studies are urokinase, streptokinase 
and alteplase (52). Urokinase has been used to a great extent in the US (53). Streptokinase has the 
disadvantage of inducing antibody formation. The recombinant tissue plasminogen activator (rt-PA) 
alteplase (Actilyse®, Boehringer Ingelheim, Ingelheim am Rhein, Germany) is the single thrombolytic 
agent registered for treatment of VTE in Norway (www.felleskatalogen.no, 
www.legemiddelhandboka.no). Alteplase has high affinity and specificity for fibrin, as fibrin-bound 
plasminogen on the clot surface accelerates the activity of alteplase substantially (figure 3).  
Theoretically this leads to less systemic effect compared to other thrombolytic agents. A previous SR 
                                                          
5  Grade 2C recommendations: Risk/benefit is unclear. Methodological strength of supporting 
evidence from observational studies. Implicate “very weak recommendations; other alternatives may 
be equally reasonable” (2). 
6 Grade 2B recommendations: “Weak recommendation, moderate-quality evidence. Desirable effects 
closely balanced with undesirable… Evidence from RCTs with important limitations… Best action may 
differ depending on circumstances…; higher quality research may well have an important impact on 
our confidence in the estimate of effect and may change the estimate”(1). 
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on t-PA for the treatment of DVT identified one study comparing high-dose vs. low-dost rt-PA (n=32), 
one comparing systemic vs. local administration of rt-PA (n=151), and 3 RCTs comparing systemic rt-
PA plus heparin vs. placebo infusions and heparin (n=169). (59). (These three trials were later 
included in the Cochrane review (52)). Use of rt-PA was found to increase chance of >50% lysis and 
complications compared to placebo. Increased dose did not increase efficacy. Local administration 
was neither more efficacious nor riskier than systemic. Based on this limited evidence the authors 
concluded that “the weight of evidence does not support routine use of rt-PA” and “there is 
insufficient evidence regarding its risks to discard this potentially effective treatment…” 
 
Figure 3 Fibrin specific thrombolysis by alteplase 
 
 
1.6 Testing treatments  
“Comparisons are the key to all fair tests of treatments” (60). 
1.6.1 Randomised controlled trials 
The most powerful method for assessing the effect of a therapy is to perform an experimental clinical 
study designed as an RCT (61). With this design patients are randomly assigned to receive the 
treatment of interest or not, and this allows comparisons to be made between two or more groups 
of patients that principally differ only in whether they have received the intervention or not, thereby 
avoiding selection bias. Likewise, all known and unknown factors that may influence the outcome, 
so-called confounding variables, will be equally distributed between the groups.  
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To avoid observation bias in RCTs, treatment allocation can be blinded. The trial may be classified 
according to the level(s) of blinding, i.e., who is unaware of allocated treatment; patient, physician, 
study investigators and/or statistician. In many trials blinding may not be ethical or feasible, resulting 
in an open design where patients and investigators know the treatment. To reduce observation bias 
in open trials, the end-point evaluators can be blinded to treatment allocation, trial results at 
previous time-points, and results of parallel assessments at follow-up.  
To improve and secure the transparency of clinical research worldwide, study protocols are since 
recently registered in open access online databases, e.g., www.clinicaltrials.gov, and a number of 
journals require studies to be registered before being considered for publication 
(http://resources.bmj.com/bmj/authors/article-submission/article-requirements).    
Another internationally accepted and warranted improvement in quality and surveillance of clinical 
research is the development of reporting guidelines, with the CONSORT guidelines for RCTs as the 
most well-known (www.consort-statement.org). (All guidelines are found through the portal 
www.equator.org). 
Finally, when designing a RCT, ethical and economic aspects have to be considered to secure patients 
rights, avoid excessive study participation and resource consumption. In addition to the principal 
investigators, this responsibility is secured through ethics committees and research sponsors.  A new 
Norwegian Law in Health research comprising all existing regulations for health research was 
approved by Parliament in 2008 and aim for increasing the quality and efficiency of the research 
process. 
1.6.2 Sample size calculation, statistical power and level of significance 
To obtain reliable results from a RCT it is crucial that the study has adequate statistical power to be 
able to detect a clinically relevant difference in effect. Power indicates the probability of detecting 
this effect, and is usually set to 80% (or 90%) (62;63). This corresponds to a probability of doing a 
type II error, i.e., accepting a false null hypothesis (to conclude that there is no difference when a 
difference exists), of 20% (or 10%).  Type II error is likely to occur if the sample size is insufficient. The 
estimated effect size is the main determinant of sample size as the required sample size is inversely 
proportional to the [estimated treatment effect]2 (61). Sample size calculation also includes a chosen 
level of significance, which is usually set to 0.05, indicating acceptance of 5% chance for rejecting a 
true null hypothesis (to conclude that there is a difference when there is no difference), i.e., type I 
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error.  Sample size calculation may then be carried out using simple formulas or computer 
programmes (62;63).  
1.6.3 Systematic review and meta-analysis 
Results of a number of RCTs evaluating the same therapy may be systematically collected into a SR 
and analysed using meta-analysis statistics. This approach leads to new information with a higher 
level of confidence than the results from single clinical studies. The rationale and advantages for SR 
are versatile, as summarised in table 6 (64;65). This synthesis of total research evidence is of great 
importance for decision makers, clinicians and researchers. The significance of systematically 
collected evidence is underlined by high-quality journals like the Lancet requiring authors to “…direct 
reference to an existing systematic review and meta-analysis. When a systematic review or meta-
analysis does not exist, authors are encouraged to do their own” (66). 
Table 6 Why do SR and meta-analysis? (64;65) 
Rationale and advantages for SR and meta-analysis 
 Condense large amounts of information 
 Quickly assimilation by healthcare providers, researchers, and policymakers 
 Explicit methods limit bias in identifying and rejecting studies 
 Efficient scientific technique 
 Show evidence that new trials are unnecessary 
 Assess generalizability of results 
 Assess consistency of results 
 Explain inconsistencies in results 
 Increase power 
 Increase precision in effect estimates 
 Improve accuracy 
 Results can be reproduced 
 Improve reliability of conclusions 
 More quickly implementation of effective healthcare 
 
1.6.4 An approach for treatment evaluation 
In summary; to answer a research question like “Is this new treatment better than current 
treatment?” a structured approach for evaluating the effects of new treatments (or other 
interventions) are needed. This will lead to a robust conclusion with high level of evidence that 
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others can use for clinical policy making, clinical practice or further clinical research. The steps for 
such an approach are summarised in table 7. 
Table 7 Steps for treatment evaluation 
Structural approach for treatment evaluation 
1 Identify or write SR 
2 Search for RCTs, if several new: update SR 
3 Search for registered trials 
4 Define protocol 
5 Register study 
6 Conduct study 
7 Report study adhering to reporting guidelines 
8 Describe main study results in trials registry 
9 Update SR 
 
1.7 Efficacy outcomes in clinical studies on deep vein thrombosis 
Traditionally the primary outcome measures in studies on antithrombotic treatment of DVT have 
been recurrent VTE, bleeding complications, and mortality (47). The majority of recurrent VTE occurs 
during the first two years after discontinuation of AC (50). However, time of follow-up in a number of 
studies is limited to only 3-12 months (47). Studies on thrombolytic therapy have used surrogate 
endpoints like patency and reflux (table 14). 
1.7.1 Postthrombotic syndrome 
Studies on antithrombotic treatment of DVT rarely report on functional and patient reported 
outcome measures. The frequency of PTS, its impact on daily activities and quality of life (QOL), and 
the associated socioeconomic burden indicate that PTS is a significant and relevant outcome 
following DVT (12-14;67). 
For assessment of PTS development, time of follow-up should be at least 2 years (8;10;11). Different 
clinical scales have been used for the diagnosis of PTS (e.g., in table 3). Most frequently employed is 
the Villalta score (68). This score has recently been discussed and recommended by the Control of 
Anticoagulation Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) 
(69). For long-term functional assessment The Society of Interventional Radiology recommends the 
use of Villalta score, preferably together with Venous Clinical Severity Score, and/or Venous Disability 
Score. These are scores derived from the CEAP-classification, see section 3.4.6 (54).  
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1.7.2 Quality of life (QOL) following deep vein thrombosis of the lower limb 
QOL is a patient reported outcome measure increasingly employed in clinical research (70), and can 
be used in both observational and experimental clinical studies (71). Patient reported outcomes are 
not only easy and reasonable to obtain, but may give relevant and valuable information on aspects 
considered of great importance from the patients’ own point of view and which are not covered by 
use of traditional clinical outcome measures. QOL is of particular interest in chronic medical 
conditions, and may be a primary or, more commonly, secondary outcome measure.  
Both generic and disease-specific QOL instruments aim at assessing multi-dimensional aspects of 
burden of disease regarding patients’ functioning and daily life including impairment of function at 
work and home, and the subsequent psychological strains and limitations in social life. It is well 
recognised that generic QOL-instruments should be used in combination with disease-specific 
instruments in clinical studies (70;71). Generic instruments, e.g., SF-36 and EQ-5D, can be used in 
both healthy individuals and patients and can compare QOL between different populations 
irrespective of diagnosis. Disease-specific instruments often assess QOL within the same dimensions, 
but with focus on aspects closely related to the disease of interest. These instruments are therefore 
more sensitive than generic questionnaires in capturing clinically relevant changes in the patient 
population of interest (71). 
To obtain reliable measures of the multi-dimensional impact of burden of disease scientifically 
rigorous measures are required (72). QOL instruments should be developed and evaluated to fulfil 
standard criteria for acceptability, reliability, validity and responsiveness in a psychometric 
evaluation (71;72). Table 8 presents a summary of the different psychometric properties that can be 
tested and their related criteria. A reliable questionnaire means that the construct of interest is 
measured consistently, as reliability describes the precision of the measurement. The validity of an 
instrument is the degree to which it measures what it was designed to measure. Responsiveness 
refers to the ability of an instrument to detect clinically important changes over time. Most 
Norwegian versions of QOL instruments are translated from English, and translation of QOL 
questionnaires should adhere to suggested guidelines (73). 
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Table 8 Psychometric evaluation of QOL measurements (71;72) 
Property Definition Assessment Criteria 
Acceptability Data quality  
Score distributions  
 
(Time for completion) 
Missing data (summary 
scores) 
Frequency distribution  
Floor and ceiling effects 
< 5% 
 
 
< 10% 
Reliability    
 Internal consistency Homogeneity of scale; extent of 
items measuring the same construct 

 
Item-total correlations 
> 0.70 
> 0.20 
 Test-retest reliability Stability over time Correlations > 0.80 
Validity    
 Content validity Representative of the domain of 
interest 
Qualitatively None 
 Construct validity Measure of a single construct 
Form a summary score 

 
Correlation 
> 0.70 
Moderate/large 
 Convergent validity Correlation with other measures of 
similar constructs 
Correlation Moderate/large 
 Discriminant validity No correlation with other measures 
of different constructs 
Correlation Small 
 Known-group differences Ability to differentiate known groups Scores groups (p-value) 
 Responsiveness Detection of clinically important 
change over time 
Change scores (p-value) 
 
Patient reported QOL is recognized as a meaningful outcome measure in long-term follow-up in DVT 
studies as a supplement to investigator-assessed measures (74). Several disease-specific instruments 
for chronic venous disease have been developed and validated, including one specifically constructed 
for acute DVT (75). Table 9 presents conclusions and summary of study details from 1 case-control 
and 10 cohort studies, including 3 validation studies, assessing QOL in patients with DVT of the lower 
limb.
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2. Aims 
Properly designed studies with long-term follow up for the evaluation of additional CDT in patients 
with acute DVT of the lower limb have been in demand for years. Routine diagnostic imaging for 
detection of acute DVT using ultrasound techniques is not always feasible. The overall objectives of 
the present work aimed at evaluating and improving diagnostic imaging and therapy of proximal DVT 
of the lower limb using scientifically sound methods. 
 
The specific aims of the thesis were: 
 To design and implement a well designed RCT for the evaluation of safety and efficacy of site-
directed thrombolysis in patients with acute iliofemoral DVT receiving CDT in addition to 
conventional AC and compression therapy (paper I). 
 To translate and assess data quality, reliability and validity of a disease-specific questionnaire 
for the assessment of QOL in patients following DVT of the lower limb (paper II). 
 To evaluate whether additional CDT increases venous patency 6 months following acute 
iliofemoral DVT (paper III). 
 To compare a novel MRI sequence with contrast-enhanced MRI in visualisation of the deep 
veins of the leg and detection of deep vein thrombosis (paper IV).  
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3. Materials and methods 
 
3.1 Recommendations and permissions 
The CaVenT Study and the MRI study were initiated after obtaining recommendations and 
permissions from Regional Ethics committee, the Data Inspectorate, the Norwegian Directorate for 
Health, and the Norwegian Medicines Agency. Liability insurance in connection with clinical trials of 
drugs was established by membership of the Drug Liability Association.  The CaVenT Study is 
internationally registered with number NCT00251771 (www.clinicaltrials.org). Quality assurance of 
the study protocol has also been secured through acceptance in Lancet’s Protocol Reviews following 
external peer-review (http://www.thelancet.com/journals/lancet/misc/protocol/07PRT-295). (With 
this the Lancet guarantees to peer review the future manuscript presenting the main results from the 
CaVenT study). 
3.2 Study design 
The CaVenT Study is an open, multicenter RCT designed to adhere to established standards for fair 
testing of treatments and published recommendations for studies on venous disease (54). After 
obtaining informed, written consent the patients were randomized to receive conventional 
treatment alone (control group) or CDT in addition to conventional treatment (interventional or CDT 
group). All patients were called for clinical follow up 6, 24 and 60 months following the thrombotic 
event.  (Data from follow up are still being collected).  
The validation study of VEINES-QOL/Sym was implemented as a small cohort study within the initial 
phase of the CaVenT Study. 
The first part of the MRI project was designed as a pilot study with healthy volunteers. The second 
part was a small cohort study of consecutively recruited patients with acute DVT. 
3.2.1 Sample size and power calculations 
Sample size of the CaVenT Study was calculated from the a priori hypothesis that frequency of PTS 
after 2 years will be at least 25% in those allocated conventional therapy compared to less than 10% 
in those given additional CDT. With a significance level of 5% and a statistical power of 80%, sample 
size calculations indicated that a total of nearly 200 patients (97.4 in each group) were required 
(62;63). Based on the a priori short-term hypothesis that venous patency after 6 months occurs in 
less than 50% in those allocated conventional treatment compared to at least 80% in those given 
CDT, it may be shown with the same significance level and statistical power as given above, that 76 
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patients are required. Reporting of patency after 6 months based on the first approximately 100 
patients with 6 months patency data was planned a priori. There were no power calculations for the 
QOL or MRI studies. 
3.3 Study participants 
The CaVenT Study has been recruiting patients from 22 hospitals within the South-Eastern Norway 
Regional Health Authority during the time period 2006-2009. Patients who met the inclusion criteria 
without any exclusion criteria were invited to participate in the studies (table 10). Those who 
accepted to participate gave written informed consent. Self-reporting QOL questionnaires from the 
first 74 patients were used in the validation study. For the MRI study 15 healthy volunteers were 
recruited among staff and medical students at Oslo University Hospital, Ullevål. Six patients with 
iliofemoral DVT were prospectively recruited from the same hospital. 
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Table 10 Inclusion and exclusion criteria for the studies 
Inclusion criteria for the CaVenT Study and MRI Study 
1. Age 18-75 years 
2. Onset of symptoms < 21 days 
3. Objectively verified proximal DVT, for the CaVenT Study: localised in  the upper half of the thigh, the 
common iliac vein, or the combined iliofemoral segment 
4. Written informed consent 
Exclusion criteria for MRI Study 
1. Any contraindication to MRI (claustrophobia, metal implants) or Vasovist® (hypersensitivity) 
 
Exclusion criteria for the CaVenT Study 
1. Anticoagulant therapy before trial entry for > 7 days 
2. Contraindications to thrombolytic therapy, including bleeding diathesis 
3. Indications for thrombolytic therapy, for example, phlegmasia cerulea dolens or isolated vena cava 
thrombosis 
4. Severe anemia (hemoglobin < 8 g/dL) 
5. Thrombocytopenia (platelets < 80 · 109/L) 
6. Severe renal failure—creatinine clearance < 30 mL/min*§ 
7. Severe hypertension, that is, persistent systolic blood pressure >160 mm Hg or diastolic blood 
pressure >100 mm Hg 
8. Pregnancy§ and thrombosis 7 days postpartum (may be included after 7 days postpartum) 
9. Less than 14 days postsurgery or posttrauma (may be included after 14 days) 
10. History of subarachnoidal or intracerebral bleeding 
11. Disease with life expectancy <24 months 
12. Drug abuse or mental disease that may interfere with treatment and follow-up 
13. Former ipsilateral proximal DVT 
14. Malignant disease requiring chemotherapy 
15. Any thrombolytic therapy within 7 days before trial inclusion 
 
*Creatinine clearance will be calculated according to the following formula:  
   Creatinine clearance (mL/min) = b · (140 – age (years)) · body weight (kg)  
    serum creatinine (μmol/L)  b = 1.04 (females); 1.23 (males) 
§ Also exclusion criteria for MRI study  
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3.4 Study procedures 
3.4.1 Randomisation 
 A random block allocation sequence for each hospital was generated by using the web site 
Randomization.com (http://www.randomization.com), with stratification for involvement of the 
pelvic veins, as the level of DVT may influence PTS development. Randomization was performed by 
the local study investigator at the recruiting investigation site by picking the lowest number of sealed 
numbered envelopes. The different local investigators were not aware of the block size of 6, which 
was constructed to secure that the centres contributing with few patients allocated patients equally 
to the two treatment arms. Patients were assigned 1:1 to control or interventional group. 
3.4.2 Routine diagnostic imaging of acute deep vein thrombosis 
Proximal DVT had to be verified using compression ultrasound, venography, CT- or MRI-venography 
in line with routines at the different trial investigation sites. 
3.4.3 Standard treatment of acute deep vein thrombosis 
Antithrombotic therapy with AC was initiated and given in accordance to local routines at the 
recruiting trial investigation site based on international guidelines (47).  AC was given as sc LMWH7
Patients were advised to wear knee-high, or thigh-high if preferred by the patient, class II (30 mmHg) 
ECS daily for at least 6 months, as stated in the study protocol. At 6 months follow-up all patients 
were urgently advised to continue with ECS for another 18 month. 
 
and simultaneous oral warfarin (Marevan®). LMWH was discontinued when INR had been in 
therapeutic range (2.0-3.0) for at least 24 hours, but was not to be given for less than a total of 4-5 
days. Warfarin was prescribed for at least 6 months.  
3.4.4 Catheter-directed thrombolysis 
Patients allocated to receive CDT were transferred to the nearest of 4 interventional centres offering 
this procedure (Aker, Ullevål and Rikshospitalet, i.e., Oslo University Hospital, or Østfold Hospital 
Trust in Fredrikstad). CDT was started on the first following working day. Meanwhile these patients 
received sc LMWH. Further details of the CDT procedure are described in paper I and III. During 
thrombolysis any overt bleeding or symptoms suspect of bleeding or pulmonary embolism were 
dealt with according to local routines. Major bleeding was defined as previously reported (85). AC 
                                                          
7 Either dalteparin (Fragmin®) 200 U/kg, or enoxaparin (Klexane®) 1.5 mg/kg 
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was then initiated as previously described in section 3.4.3 within 1 hr following completion of 
thrombolysis.  
3.4.5 Non-invasive assessment of veins at follow-up 
Non-invasive assessments of the veins were performed after 6 months ± 2 weeks by an angiologist 
with no previous contact or knowledge of the patients’ treatment allocation or medical history. To 
further secure an unbiased evaluation of outcomes, the patients were explicitly told not to reveal 
which treatment they had been given.  
The venous system was examined using ultrasound and air-plethysmography. Ultrasound was used 
for the assessment of postthrombotic wall-thickening, intraluminal hyperechoic structures, flow, 
compressibility, and incompetence.  Venous flow was graded as spontaneous, forced (on peripheral 
compression), or absent (53). Incompetence was evaluated with the patient in standing position, and 
reflux was defined as reversal of the velocity curve lasting longer than 0.5 seconds following 
standardised distal pneumatic decompression (86). Functional obstruction of the veins was assessed 
by using air plethysmography (87;88). Assessment of venous patency included compressibility, flow, 
and venous obstruction. Patients having any of the following: incompressibility of the femoral vein, 
no iliofemoral venous flow and/or functional venous obstruction, were classified as not having 
regained iliofemoral venous patency. Patients with duplicate femoral veins with normal 
compressibility and flow in at least one course and without functional obstruction were considered 
successfully recanalized. 
3.4.6 Clinical evaluation of postthrombotic changes 
At follow-up, information was obtained regarding comorbidity of the lower limb, recurrent venous 
thromboembolism or new diagnosis of cancer. Evaluation of development of chronic venous disease 
and PTS was assessed by CEAP-classification (89) and Villalta score (68), respectively. The CEAP 
classification includes assessment of Clinical (dermatological) signs, Etiology, Anatomic distribution 
and Pathophysiologic dysfunction, see table 11 for details.  
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Table 11 The CEAP classification of chronic venous disorders 
Clinical signs Class 0 No visible or palpable signs of venous disease 
Class 1 Teleangiectases or reticular veins 
Class 2 Varicose veins 
Class 3 Edema 
Class 4 a. pigmentation, eczema 
b. lipodermatosclerosis, atrophia blanche 
Class 5 Healed ulceration (and skin changes as defined above) 
Class 6 Active ulceration (and skin changes as defined above) 
Etiological classification Congenital, primary, secondary 
Anatomic distribution Superficial, deep, or perforator, alone or in combination 
Pathophysiological 
dysfunction 
Reflux or obstruction, alone or in combination 
 
The Villalta scale was developed for assessment of PTS and consists of five patient-rated venous 
symptoms of the affected leg (pain, cramps, heaviness, paresthesia, pruritus) and six clinician-rated 
signs (pretibial edema, skin induration, hyperpigmentation, pain during calf compression, venous 
ectasia, redness). The symptoms and signs are each rated on a 4-point scale (0 = none, 1 = mild, 2 = 
moderate, 3 = severe). Points are summed to produce a total score. Patients are classified with PTS if 
the score is or if a venous ulcer is present. A score of 5-14 indicates mild/moderate PTS, whereas 
a score of the presence of a venous ulcer regardless of total score indicates severe PTS.  
3.4.7 Assessment of quality of life 
Health related quality of life was assessed by the patients completing the self-reporting 
questionnaires EQ-5D (90) and VEINES-QOL/Sym (72) in a clinical setting at baseline and follow up. 
The Norwegian versions of the two instruments are presented in the appendix. 
3.4.8 MRI 
MRI was performed in a 1.5 T whole body scanner (Philips Intera, software release 2, Philips, Best, 
The Netherlands). The participants were scanned in a supine position with feet first. A 1.5 T body coil 
(Synergy Body Coil, Philips, Best, The Netherlands) was positioned for imaging at three different 
positions covering the calves, thighs and pelvis. All images were obtained in the axial plane. Contrast-
enhanced images were obtained under conditions corresponding to the non-enhanced sequence. 
Gadofosveset trisodium (Vasovist®, Bayer Schering Pharma AG, Berlin, Germany) was administered at 
0.12 ml/kg (0.03 mmol/kg) body weight and injected by hand through a cannulated cubital vein for 
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25-30 sec followed by a 25-30 ml saline flush, in accordance to the Norwegian Medical Agency 
(www.legemiddelverket.no) and previous reports from the manufacturer (91). Scanning was initiated 
after 3 minutes delay. 
3.4.9 Ultrasound in MRI study 
Additional and complete compression ultrasound was performed in all patients in the MRI study on 
both lower extremities’ deep veins covering the proximal part of the calves up to the inguinal 
ligament (18). The examinations were performed on an Acuson Seqoia no. 512® (Siemens, Germany) 
with linear (5-8 MHz, CD 4-7 MHz), curved (2-4 MHz, CD 1.75-4 MHz), and sector (2.5-4 MHz, CD 2.5-
4 MHz) probes. Direct signs of acute DVT were defined as incompressibility of vein, echoic content of 
vein lumen, and no detection of flow in pelvic veins and ICV. Indirect signs included dilatation of deep 
veins. 
3.4.10 Statistical analyses 
Statistical analyses were performed using the statistical package SPSS version 15 (SPSS, Chicago, 
Illinois, USA). Findings with p-values lower than 0.05 were considered statistically significant. When 
comparing dichotomous variables in the two treatment groups, a two-sided Chi-square test was 
used. When comparing continuous variables, a two-sided Mann-Whitney test was used.   
The analyses from the validation of VEINES/QOL/Sym included internal consistency assessment using 
item-total correlation and Cronbach’s alpha. Test-retest reliability was assessed by calculation of the 
intra-class correlation coefficient. Construct validity was assessed as correlation with the EQ-5D, the 
Villalta score, CEAP classification, and presence of comorbidity of the lower limb. The t-test was used 
for binary groups and Spearman’s correlation for nominal groups. 
Statistical differences in vessel visualisation and image quality on MRI were calculated using 2-tailed 
Wilcoxon signed ranks test. Agreement in vessel visualisation between b-TFE and CE-FFE images was 
calculated as percent agreement. An inter-observer reliability analysis using the Kappa statistic was 
performed to determine consistency among the two observers in diagnosing DVT. 
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4. Summary of results 
 
4.1 Paper I 
Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis - the 
CaVenT Study: Rationale and design of a multicenter, randomized, controlled, clinical 
trial (NCT00251771) 
Properly designed RCTs are needed to evaluate the clinical efficacy and safety of additional CDT 
compared with conventional treatment with AC and ECS in patients with iliofemoral DVT. Clinical 
efficacy should be assessed as a functional outcome of the affected limb. Totally 200 patients are 
required to detect a reduction in PTS from 25% to 10% 2 years following the thrombotic event. The 
CaVenT Study employs standardized and verifiable methods for outcome assessment including 
venous patency, incompetence, obstruction, and PTS. Implementation of the CaVenT study will be a 
substantial contribution towards improved evidence-based practice in the treatment of acute 
proximal DVT of the leg. Any documentation of improved functional outcome will have a significant 
impact on clinical practice and may lead to a modification of existing international guidelines. 
 
4.2 Paper II 
Assessing burden of illness following acute deep vein thrombosis: data quality, reliability 
and validity of the Norwegian version of VEINES-QOL/Sym, a disease-specific 
questionnaire  
The data quality, reliability and validity of the Norwegian version of VEINES-QOL/Sym were assessed 
in 74 patients with deep vein thrombosis (DVT). Items had low levels of missing data, with the great 
majority being under 3%. Item-total correlations ranged from 0.41 to 0.78 with the exception of 0.29 
for the symptom item ‘night cramps’. Internal consistency was supported by Cronbach’s alpha of 
0.88 and 0.94 for VEINES-Sym and VEINES-QOL, respectively. Test–retest reliability assessed for 40 
patients gave intra-class correlation coefficients of 0.83 and 0.88 for VEINES-Sym and VEINES-QOL, 
respectively. VEINES-Sym and VEINES-QOL were strongly correlated with EQ-5D total scores. There 
were moderate to large correlations with Villalta scores and small to moderate correlations with the 
CEAP classification. Six months after the thrombotic event, 21 (28.4%) patients had developed PTS 
according to Villalta score, and this was significantly associated (p < 0.01) with a reduction in both 
VEINES scores. 14 patients reported comorbidity of the lower limb, and this was associated with a 
reduction in both scores; reduction being significant for VEINES-QOL (p < 0.05). 
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4.3 Paper III 
Additional catheter-directed thrombolysis in deep vein thrombosis increased patency - 
short-term results from the CaVenT Study: an open, randomised controlled trial 
In 50 patients who were randomised to additional CDT, grade III (complete) lysis was achieved in 24 
and grade II (50-90%) lysis in 20. One patient suffered major bleeding and 3 had clinically relevant 
bleeding related to the CDT procedure. Patency of the iliofemoral vein after 6 months was found in 
32 of 50 patients (64.0%) in CDT group and in 19 of 53 (35.8%) in control group. This corresponds to 
an absolute risk reduction of 28.2% (95% confidence interval 9.7 to 46.7%, P=0.004). Functional 
venous obstruction was found in 10 (20.0%) in CDT group and 26 (49.1%) controls. This corresponds 
to an absolute risk reduction of 29.1% (20.0 to 38.0%, P=0.004). Femoral venous reflux was found in 
approximately 60% and did not differ significantly between the two groups. 
 
4.4 Paper IV 
MRI of veins and thrombosis 
Fifteen healthy volunteers underwent MRI without (b-TFE) and with contrast-enhancement (CE-FFE) 
for imaging of the deep veins of the lower limb. Vena cava inferior (VCI) was only partially visualised 
in 7 and 4 volunteers on b-TFE and CE-FFE, respectively (p<0.008). The great majority of femoral and 
calf veins and all pelvic and popliteal veins were completely visualised on both sequences. Percent 
agreement between the two techniques was 50.0 % for VCI, and 90.0-100.0 % for other segments. 
For both techniques poorest image quality was obtained in the pelvis. Contrast-to-noise ratio was 
higher on b-TFE compared to CE-FFE; the difference being significant in calf images (p=0.036). 
Sensitivity was 100% for proximal DVT with both MRI methods. Specificity was 70-100% (CE-FFE) and 
80-100% (b-TFE) for femoral DVT. Interobserver reliability was Kappa 1.0 (b-TFE) and 0.9 (CE-FFE) for 
proximal DVT. Results were overall poor for distal DVT. 
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5. Discussion 
 
5.1 Study design for evaluation of venous thrombolysis 
There is no robust evidence on clinical efficacy of additional CDT in iliofemoral DVT as controlled 
trials with long-term follow-up are completely lacking (14;52). A number of case-series reports on 
technical success and effective thrombolysis at the cost of a small increase in bleeding complications 
(see section 5.3 and table 14). The long-term follow-up in these reports has focused on patency rates 
and the need for re-interventions. Hence, very little is known on clinically relevant efficacy in terms 
of functional outcome of the affected leg following venous thrombolysis. Properly designed RCTs are 
required to fill this gap in evidence, otherwise CDT will continue to be a cost demanding, 
experimental treatment prone to lack support by policy makers and payers, e.g., as in Canada and 
Netherlands (personal communication Philip Wells and Menno Huismann),  and we can “... continue 
to base our decisions on an endless row of small case series and retrospective reviews of 
heterogeneous data” (92).  
RCTs may be criticized for lacking generalizability due to eligibility criteria that may not resemble the 
“real clinical world” (93). In the CaVenT study the inclusion and exclusion criteria were aimed at 
allowing a representative patient population with regards to gender, age and risk factors. This is in 
contrary to several of the case series on CDT. Patients with an increased risk of bleeding were not 
recruited. Patients with advanced or chemotherapy demanding cancer or drug abuse were not 
included because of high risk of rethrombosis and potentially reduced compliance and loss to follow-
up.  These groups of patients are not likely to be offered CDT in clinical practice due to the same 
reasons. Rethrombosis has been shown to increase risk of PTS. Hence repeated DVT complicates end-
point assessment of PTS and was tried to be avoided by not recruiting patients with previous 
proximal ipsilateral DVT.  Recurrent DVT of the same limb during follow-up was not possible to avoid.  
In spite of aiming at a widely representative population in the CaVenT Study, recruitment rates were 
lower than hoped for during the whole period of 2006-2009 (92). In average only 1 patient has been 
recruited per week. We are aware of that a number of patients denied participation. Other and 
probably more important challenges have been of organizational matter as several of the 
participating centers are not supplied with designated personnel, clinics or wards for patients with 
VTE, and the patients are often treated in general medicine departments. Finally, the 
implementation of the CaVenT Study had to take place in between all other daily tasks for the local 
trial site investigators and their colleagues. 
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Based on a checklist for critical appraisal of RCTs the CaVenT Study is found to meet accepted 
standards, as presented in table 12 (www.kunnskapssenteret.no).  
A crucial step in RCT design, which is not covered in this check list, is the estimation of the effect size 
of the therapy being tested. This estimate has to be deduced from previous knowledge about the 
disease; i.e., DVT and PTS.  When planning and designing the CaVenT Study, it was hypothesized that 
additional CDT reduces the absolute risk of PTS with 15%; from 25% in control group to 10% in the 
intervention group. As this estimate is associated with uncertainty, the CaVenT Study may be too 
small to detect the difference, and we may accept a false null hypothesis that there is no reduction in 
PTS following CDT (i.e., type II error). The risk of doing a type II error was set to 20% (63;94).  If 
reducing this risk to 10%, the sample size would have to increase from 200 to 260 (with a level of 
significance of 5%), leading to a much greater demand on time and other resources to implement the 
CaVenT Study. It has been commented that severe PTS may be a much more clinically relevant 
outcome measure than PTS itself, however, a study demonstrating a reduction of severe PTS in terms 
of venous ulcers from 6% to 3% would require about 2000 patients, and would be impossible to carry 
out with the available resources in our region (92). 
We hypothesized that CDT reduces PTS from 25% to 10%. In case we detect this difference or even a 
smaller effect size, i.e., an absolute risk reduction of 5, 10 or 15 %; this would correspond to a 
number needed to treat of 20, 10 or 6.7, respectively, to avoid one case of PTS. This has to be 
weighed against the risks and complications adhering to CDT. Whether CDT is a cost-effective 
intervention will be assessed in a planned health economic evaluation when the future long-term 
results of the CaVenT Study are available. Finally, how to weigh additional bleeding complications 
against PTS reduction and improved QOL is not clear. 
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5.2 Postthrombotic syndrome as outcome measure 
PTS is recognized as the most common complication following DVT, but existing knowledge about 
this chronic, clinical entity is limited (8). This can be explained by focus on recurrent VTE as main 
efficacy outcome of clinical trials on DVT treatment (47). The Cochrane Review from 2004 identified 
only 2 RCTs that reported on PTS following additional systemic thrombolysis (figure 2) (52). The study 
of Arnesen and colleagues (95) was considered to be of highest quality. This sparse evidence 
supports our hypothesis that additional CDT may reduce PTS from 25 % to 10 % compared with 
standard AC and ECS.  
Reported incidence of PTS has been variable, but prospective studies indicate development of PTS in 
20-50% following DVT (8). Two open RCTs comparing treatment with additional ECS to AC alone have 
brought new insight and are often referred to. They both found that 2 years of ECS reduced PTS with 
nearly 50%; see table 4 (10;11). This indicates that ECS is effective therapy, and compression is 
consequently recommended for 24 months following proximal DVT (grade 1A recommendations) 
(47). Unfortunately, there seems to be delay in implementing long-term ECS therapy in 
postthrombotic care (personal experience). 
There is no established definition or gold standard test for PTS, and to infer and compare frequency 
of PTS across studies is therefore problem-ridden. It is suggested that initial pain and swelling for 
acute DVT may last for up to 3-6 months, and that PTS should not be diagnosed until after this time 
(96). There is evidence indicating that the great majority of cases of PTS usually manifest within 2 
years after DVT  (10;96), but PTS may develop or deteriorate beyond 2 years (97). 
A number of PTS definitions based on combinations of various clinical symptoms and signs, possibly 
combined with functional tests of the veins, have been suggested (97). This is illustrated in table 13 
by four trials previously referred to in the thesis, employing four different definitions of PTS. The use 
of Villalta score is now supported in recent reporting guidelines for endovascular treatment of 
venous thrombosis from the Society of Interventional Radiology (54) and in recommendations for 
standardization of the measurement of PTS in clinical studies from the Control of Anticoagulation  
Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH, Vienna, July, 2008) 
(69). The CaVenT Study mainly adhered to these recommendations, though there was no training of 
trial investigators in use of Villalta score, patients wore ECS when attending follow-up which may 
mask signs like swelling and vein dilatation, and the end-point evaluator was not blinded to which leg 
had suffered from DVT. 
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Table 13 Examples on how PTS has been defined in previous, important studies 
Year 1st author Definition PTS 
1982 Arnesen (95) Subjective complaints and clinical signs; 
no/moderate/serious, including ulcer 
1997 Brandjes (11) Symptoms and signs scored in a form combining 
components of earlier scoring systems 
1998 Schweizer (98) Patients described own symptoms; 
no/slight/moderate/serious, including ulcer 
2004 Prandoni (10) Villalta score 
 
Further, also arguing for the use of Villalta score for measurement of PTS, previous studies reporting 
on measurement properties of the Villalta score was recently reviewed (99). The available data were 
found to be “consistent in supporting that Villalta score is a reliable, valid, acceptable and responsive 
measure of PTS in patients with previous, objectively confirmed DVT”, while the reliability of the 
symptoms components, numeric points for ulcer severity (e.g. no ulcer, healed ulcer, one open ulcer, 
> 1 open ulcer) to discriminate among severe forms of PTS, and responsiveness to clinical changes 
need further research.   
Based on a number of observational studies, the only risk factor clearly associated with PTS 
development is repeated ipsilateral DVT, increasing the risk up to six fold (97;100). This was recently 
shown in a prospective cohort study of 387 patients (14). This study also found that more severe 
venous symptoms and signs 1 month after DVT, extensive iliofemoral DVT, higher BMI, older age and 
female sex predicted worse postthrombotic scores over time. Another and similar study of 406 
patients found that proximal DVT, male sex, and high D-dimer levels were independently associated 
with PTS development in patients with a first time DVT (101). The CaVenT study is not powered to 
detect possible risk factors for PTS, but future data should be analyzed with regards to the above 
mentioned predictive co-factors.  
54 
 
5.3 Short-term results as surrogate outcome measure 
Postthrombotic persistent venous obstruction and/or incompetence have been regarded as the 
predispositions for PTS development (8). From this follows that regaining patency and/or salvaging 
valves of the deep veins is likely to be important in preventing PTS and this founded the basis for the 
short-term hypothesis of the CaVenT Study. The relationship between immediate or mid-term 
patency and subsequent development of PTS remains unclear as no studies have investigated 
relationship between patency and long-term clinical outcome (52;102). A  SR from 2007 compared 
pooled data from observational studies on CDT with results from RCTs on systemic venous 
thrombolysis and found that the pooled CDT data showed higher rates of complete early opening of 
occluded veins, lower prevalence of PTS, but more often minor bleeding complications (102). The 
authors concluded that CDT seems more beneficial than systemic administration, and an advantage 
is the option for adjunctive angioplasty. This conclusion should be interpreted with caution because 
of heterogeneity and other methodological limitations, i.e., few, small and mainly observational 
studies.  
Following standard treatment of DVT 6 and 12 months patency are reported to be 38-50% (1). 
Patency following treatment with CDT has been assessed in at least 14 case series, as summarized in 
table 14. Three of these series reported 6 months patency to be 83%, 85% and 100% (103-105), while 
the majority of the series assessed patency after 2 years. These studies have a number of 
methodological weaknesses including lack of representative control groups, substantial loss to 
follow-up, small samples, high probability of selection bias, non-blinded assessments of outcome at 
all levels, use of variable thrombolytic and adjunctive procedures, and unclear and variable 
definitions and methods of assessment of patency, as shown in table 14.   
In the CaVenT study additional CDT increased 6 months patency from 38.5% to 64.0% (p=0.004). 
Corresponding numbers in the smaller RCT of Elsharawy was 12% to 72% (p<0.001), with “no 
obstruction or reflux” indicating patency.  Based on our study protocol with non-invasive assessment 
of the deep veins at follow-up, we defined iliofemoral patency as deep vein segments with flow on 
Doppler, compressibility on ultrasound and no sign of venous obstruction on air-plethysmography. 
This is likely to be a conservative and strict definition that may contribute to the apparent differences 
in results compared to other studies. However; this definition is clear, and it is verifiable for 
subsequent research. Finally, the finding among our controls of 38.5% patency is in line with previous 
studies (1).  
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We found that functional venous obstruction was reduced from 49.1% to 20.0% (p=0.004) following 
additional CDT. In the Elsharawy et al study moderate obstruction was found in more than 20% of 
patients in both groups (p=0.027), whereas severe obstruction was reduced from 59% to 6% 
(p=0.001). In the CaVenT study venous incompetence after 6 months was found in approximately 
60% of patients in both treatment groups. This is in contrast to previous assumptions of valve salvage 
from rapid removal of thrombus, and to the findings of Elsharawy et al who found that CDT reduced 
reflux from 41% to 11% (p=0.042).  The results of these two RCTs are not easy to compare, as the 
relatively small sample sizes and different definitions and measures of postthrombotic venous 
functions are likely to explain the seeming differences in results. 
Another unsettled aspect is how the CDT procedure should be performed with regards to choice and 
dose of thrombolytic agent and concurrent antithrombotic infusion. In the CaVenT Study patients 
received a weight adjusted dose of alteplase of 0.01 mg/kg/h and maximum 20 mg/24h. This is 
slightly lower than in case series describing alteplase infusion in CDT (106-109). Chang et al and the 
Danish reports of 2005/2009 employed pulse spray technique to shorten overall infusion time, 
however total dose of alteplase does not seem to have been reduced. Concomitant infusion of 
heparin was used in most of the series, except in the RCT of Elsharawy and in the American registry 
study where this was left to the discretion of the operator (53;55). In the CaVenT Study heparin dose 
was adjusted to keep APTT at 40-60 sec, while others have aimed at 75-100 sec (110), 50-80 sec 
(111), 60 sec (109), or 50-70 sec (112). Whether the more careful approach of the CaVenT Study with 
lower thrombolytic and antithrombotic dosage explains the apparent smaller effect in valve salvage 
and improved patency cannot be ruled out, but future results will indicate whether the approach was 
a safer one with reduced frequency of bleeding.  
The CaVenT patients received CDT at the nearest among four participating intervention centres, all 
with several years of experience with venous CDT, indicating that beginners’ problems in performing 
the procedure was avoided and did not influence on the results. 
There is agreement that deep venous reflux should be assessed by Doppler ultrasound, but 
plethysmographic technique has also been used as in the study of Elsharawy. Consensus guidelines 
suggest that both manual and automatic compression and decompression of the calf may be used , 
and a cut-off of retrograde flow of 0.5 sec following decompression of the calf (86). In the CaVenT 
Study reflux was assessed in line with consensus guidelines. Reflux may be found in patients with no 
previous DVT, indicating that other factors than previous thrombosis may also contribute to venous 
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valve incompetence (113). The time interval from acute onset of venous thrombosis to deterioration 
or disintegration of valve function remains uncertain.  
Studies that have looked into the contribution of venous obstruction and incompetence in PTS 
development have found indications of incompetence being of lesser importance than obstruction 
(114;115). This is in keeping with the fact that the valves of the deep veins are mainly located in the 
paired calf veins, that only one valve may be found in a minority of external iliac veins, and that one 
popliteal valve and 1-4 femoral valves are normally found (116). Accordingly, CDT is actually directed 
towards proximal vein segments with very few valves to salvage, suggesting that venous 
incompetence is not among the important outcomes when assessing efficacy. 
Finally, one should keep in mind that the underlying pathophysiological mechanisms for 
development of PTS are more complex than merely obstruction and/or reflux, and are likely to 
include endothelial dysfunction, deranged lymphatic function, associated arterial occlusive disease, 
joint disorders, inflammation and metabolic disturbances (117). Mechanisms remain unclear, but two 
recent reports indicate that inflammatory mechanisms are involved (118;119). As the CaVenT study 
was not designed to further elucidate possible underlying mechanisms for PTS development 
subgroup analyses should be interpreted with caution, but data will be explored when available.
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5.4 Measurement of quality of life after DVT 
Previous to the CaVenT Study there was no available disease-specific questionnaire in Norwegian for 
assessing QOL in patients with chronic venous disease. The frequently used generic instruments SF-
36 and EQ-5D were both available in previously validated Norwegian versions (www.euroqol.org) 
(123). The EQ-5D was chosen because of its smaller size and its utility in cost-effectiveness analysis 
(124).  
The VEINES-QOL/Sym was modelled after SF-36 with regards to “the content and format of 
questionnaire items and response scales” (125). It is validated in both English and French versions, 
and its use has been reported in 3 large cohorts with DVT patients (summarized in table 8). Four 
other disease-specific questionnaires have been validated and/or employed in DVT studies, however, 
using the terms “venous thrombosis” and “quality of life” combined with these instruments and/or 
1st author in a Medline search did not reveal more documentation regarding experience with these 
instruments in DVT studies than presented in table 8, though existing evidence suggest high quality 
of a number of these with regard to how they were developed and tested. Hence, none of these 
instruments were employed in the CaVenT Study because of sparse documentation compared to the 
VEINES-QOL/Sym questionnaire. Finally, use of VEINES-QOL/Sym and EQ-5D is supported by recent 
reporting guidelines on endovascular treatment for DVT of the lower limb (54). 
Translation of questionnaires should be carried out following the principle of translation-back 
translation, as described in suggested guidelines (73). The Norwegian translation mainly adhered to 
these; we used both informed and uninformed translators, including one with English as first-
language, followed by synthesis of the translations. No problematic issues arose during this process 
or when testing the questionnaire on 11 patients with previous DVT in a pilot study. 
Sample size of studies validating patient-reported QOL instruments is variable (table 8), and the 
required sample size of studies assessing measurement properties is not clearly defined (126). Our 
validation study did not include a sample size calculation, but the sample size was comparable to 
other studies on translated instruments, and in line with tentative guidelines (73;126). As discussed 
below, our results were overall consistent and in line with the results of previous psychometric 
evaluation of VEINES-QOL/Sym (72), supporting that the sample population was adequate.  
In our study we obtained good data quality with low levels of missing data indicating acceptability of 
the Norwegian version. We did not register how many minutes it took the patients to complete the 
questionnaire. As in the original work of Kahn et al (72) most item-total correlations were > 0.4, all 
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of the questionnaire in our study as well. Likewise, test-retest reliability gave satisfactory intra-class 
correlation coefficients of >0.8. Construct validity in our study was supported by statistically 
significant moderate to large levels of correlation of VEINES-QOL/Sym scores with EQ-5D scores, both 
total and individual items, Villalta score, CEAP classification and presence of co-morbidity of the leg 6 
months following DVT. In the original work construct validity was indicated by correlations with SF-36 
scores (higher levels for physical than mental health scores), low correlations with age and gender, 
and an expected gradient of lower scores with increasing severity of PTS as assessed with Villalta 
score. No test for statistical significance was presented for these correlations, and assessment was 
based on 1 and 4 months follow-up. Evaluation of responsiveness of the Norwegian version of 
VEINES-QOL/Sym will be assessed when 2 years data from the CaVenT Study are available. 
Some patients of the CaVenT Study were confused when completing the baseline questionnaire 
during the acute phase as most items focus on the previous 4 weeks, and most patients, including all 
patients of the CaVenT Study, have had shorter duration of symptoms by the time of diagnosis. 
However, this did not seem to affect the psychometric properties of the instrument in other reports 
including baseline scores (72), but needs to be kept in mind when assessing change in patient 
reported QOL in interventional studies on DVT treatment. 
The developers of the VEINES-QOL/Sym instrument have previously pointed out that future work 
should be undertaken to establish population norms for both scores in DVT patients in different 
countries, to further evaluate the ability of the VEINES-QOL/Sym to detect change and to test the 
questionnaire in independent patient samples to confirm its psychometric properties (72). Our work 
contributes to the latter, but we do not know of other recent reports on these issues.  
Additionally, to find out what represents important changes to the patients, and not only statistically 
significant changes, it would be of benefit to perform studies that look more into the meaning of 
differences in VEINES-QOL and -Sym scores. The SF-36 scores range from 0-100 and a difference of 3–
4(5) points in the score for physical health has been suggested to be (clinically) meaningful to 
patients, though this issue is not straightforward (74;127). Together with previous results in patients 
with chronic venous disease, Kahn and colleges inferred that the same difference is meaningful for 
the VEINES-QOL/Sym scores, and employed this when estimating effect size and calculating sample 
size for their recent study on determinants of QOL following DVT (74). They showed that mean 
VEINES-QOL/Sym scores increased from baseline with 5.9 and 4.7 points, respectively, in patients 
with PTS after 2 years compared to 3.6 and 2.0 in patients without PTS. The scores also increased 
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among categories of severity of PTS. These differences were interpreted to be clinically meaningful. 
However; to infer that a meaningful difference in SF-36 scores directly applies to the VEINES-
QOL/Sym scores may not be correct. As it has been shown that minimal important difference may 
vary even between sub scales of one instrument (Kvam AK et al, unpublished results), meaningful 
difference is likely to differ between two instruments, and even between the two VEINES-QOL and –
Sym scores. In summary, the meaningful interpretation of the two VEINES scores is not clearly 
established and needs further investigation. 
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5.5 Detection of DVT with MRI 
In clinical practice ultrasound is the method of choice for DVT detection of the lower limb (17).  
Ultrasound has the advantage of no side-effects, radiation or contrast agent, low costs, and high 
availability. The method has limitations as it is highly investigator dependent and with relatively low 
ability to visualize deeper structures compared to the other diagnostic imaging modalities, i.e., 
venography, CT, and MRI. As some cases are inconclusive, alternative methods of imaging is 
required. Conventional and CT venography expose the patient to radiation and potentially 
nephrotoxic contrast agent. Besides the very rare complication nephrogenic systemic fibrosis, which 
has been reported following injection of MRI contrast agent in patients with severe kidney failure, 
MRI is without side-effects, and has been shown to perform well in patients with inconclusive results 
on ultrasound (26). It is therefore reasonable to choose MRI if ultrasound is inconclusive in patients 
with known or suspected kidney failure. 
Our MRI study was performed as a pilot study on healthy volunteers and a small number of patients 
with verified proximal DVT on ultrasound. We found that image quality and visualisation of the deep 
veins of the lower limb were mainly adequate and comparable when comparing a novel balanced 
sequence with contrast enhanced MRI. When applying the same methods on patients with an 
ultrasound verified proximal DVT we found that calf level imaging was problematic with unreliable 
inter-observer rating and low sensitivity and specificity. The low inter-observer agreement was 
achieved in spite of instructions on reading with both observers.  More extensive instruction may 
improve this.  
Use of so called blood pool contrast agent has not previously been reported in DVT detection, but is 
likely to produce comparable or better results than traditional MRI contrast due to its longer 
intravascular phase. Use of blood pool MRI contrast for DVT detection cannot be supported based on 
the present study, as the non-enhanced balanced sequence showed comparable inter-observer 
agreement and diagnostic properties. Our results indicated good diagnostic properties of both MRI 
methods in proximal DVT, but due to the study’s methodological limitations the strength of results is 
weak. In summary, the MRI study and results are comparable to other studies on MRI in DVT 
detection (table 3).  
63 
 
6. Conclusions and future perspectives 
 
From the work of this thesis it may be concluded that: 
 The CaVenT study is properly designed to demonstrate efficacy of additional CDT in the 
treatment of iliofemoral DVT.  
 A Norwegian version of VEINES-QOL/Sym was a valid and reliable questionnaire for 
assessment of QOL in patients with previous DVT. 
 Additional CDT is effective in regaining patency after 6 months. 
 MRI with a novel balanced technique is comparable to contrast enhanced MRI in 
visualization of the deep veins of the lower extremities.  
 Both MR techniques performed well in proximal, but not in distal DVT. 
 
6.1 Future studies on diagnostic imaging of DVT 
To confirm the indicative results of our work on balanced and contrast-enhanced MRI in DVT 
detection, a study adhering to the STARD initiative (www.stard-statement.org) for complete and 
transparent assessment of clinical, diagnostic accuracy in line with level 2 diagnostic efficacy (see 
table 4) should be performed.  Such a study may also involve D-dimer levels and assessment of 
clinical probability. It may be of even greater importance to perform outcome studies that evaluate 
the routine diagnostic methods of ultrasound and CT in VTE diagnostic combined with D-dimer and 
clinical probability. Finally, further research on MRI for visualisation and characterisation of the 
thrombus itself may lead to novel insight into e.g. thrombus age and lysability, as so far preliminary 
reported for the MRDTI technique (25). At the present, we are not planning further MRI evaluations. 
 
6.2 Ongoing and future studies on DVT treatment 
Fortunately, at the moment there are a number of ongoing studies that will produce results with 
major and novel contributions to the knowledge on DVT treatment: 
 The CaVenT Study (NCT00251771, www.clinicaltrials.gov) 
The completion of the CaVenT Study will give clinically relevant results on efficacy and safety 
for CDT in iliofemoral DVT. The CaVenT Study will also provide patient-based data for a full 
economic evaluation (cost-effectiveness study) (128) of CDT, and this has previously not 
been reported as studies assessing economic burden of VTE and its complications have 
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employed retrospective observational cohort design and literature-based models only 
(12;67;129).  
 The ATTRACT Study (NCT00790335, www.clinicaltrials.gov) 
The upcoming and very similar, but larger American ATTRACT Study will start recruitment in 
2009. As with CaVenT, ATTRACT will produce long-term clinically relevant results on PTS 
development, QOL and cost-effectiveness.  
Both studies may be able to identify predictive factors for the development of PTS, but this is 
not among their primary aims. Likewise, results on use of adjunctive endovascular 
procedures like angioplasty, stent, thrombectomy, and cava filters along with different 
methods of administrating alteplase, e.g., continuous infusion, pulse spray technique, will be 
available as secondary end-points. 
 The SOX Trial (NCT00143598, www.clinicaltrials.gov) 
Novel and valuable insight into PTS development will be provided by the ongoing and first 
ever double blinded placebo controlled study on ECS in proximal DVT; the SOX Trial.  
 
All these studies are depending on high quality implementation and long-term follow-up! When they 
are completed, analyzed and reported, and if the results indicate need to change current guidelines, 
they should be followed by studies investigating uptake and implementation of thrombolytic and 
compression therapy in clinical practice, including evaluation of different implementation 
approaches. This will in the end secure an improved and evidence-based practice for DVT patients. 
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Appendices 
a. VEINES QOL/-Sym 
Besvar hvert spørsmål nedenfor ved å krysse av svaret som angitt. Hvis du er usikker på hva du skal svare, vennligst 
svar etter beste evne.
Disse spørsmålene er om din oppfatning av beina dine.
1. I løpet av de 4 siste ukene, hvor ofte har du hatt noen av disse plagene i beina?
(Sett ett kryss på hver linje) Daglig
Flere 
ganger i 
uka
Omtrent én 
gang i uka
Sjeldnere 
enn én gang 
i uka Aldri
1. Tunge bein 1 2 3 4 5
2. Vondt i beina 1 2 3 4 5
3. Hevelse 1 2 3 4 5
4. Kramper om natta 1 2 3 4 5
5. Varme eller brennende følelse 1 2 3 4 5
6. Urolige bein 1 2 3 4 5
7. Banking 1 2 3 4 5
8. Kløe 1 2 3 4 5
9. Prikking 1 2 3 4 5
2. Når på dagen er plagene i beina mest uttalte? (Sett ett kryss)
1 Når jeg våkner 4 Om natta
2 Midt på dagen 5 Når som helst i løpet av dagen
3 På slutten av dagen 6 Aldri
3. Sammenlignet med for ett år siden, hvordan vil du vurdere dine plager i beina nå? (Sett ett kryss)
1 Mye bedre nå enn for ett år siden 4 Noe verre nå enn for ett år siden
2 Noe bedre nå enn for ett år siden 5 Mye verre nå enn for ett år siden
3 Omtrent det samme nå som for ett år siden 6 Jeg hadde ingen plager i beina i fjor
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4. Følgende spørsmål gjelder daglige aktiviteter. Setter plagene i beina begrensninger for dine daglige aktiviteter? 
Hvis « ja », i hvilken grad?
(Sett ett kryss på hver linje)
Jeg jobber 
ikke
JA, 
begrenser 
meg mye
JA, 
begrenser 
meg litt
NEI, 
begrenser 
meg ikke
a. Daglige aktiviteter på jobb. 0 1 2 3
b. Daglige aktiviteter hjemme (husarbeid, småjobber, 
hagearbeid, o.l.)
1 2 3
c. Fritidsaktiviteter hvor du må stå lenge (selskap, ta buss, handle o.l.) 1 2 3
d. Fritidsaktiviteter hvor du må sitte lenge (kino, teater, på reise o.l.) 1 2 3
5. 3. I løpet av de 4 siste ukene, har du hatt noen av disse problemene i jobb eller i daglige aktiviteter på grunn av
plagene i beina?
(Sett ett kryss på hver linje) JA NEI
a. Redusert arbeidstid eller tid til andre aktiviteter 1 2
b. Gjennomført mindre enn du skulle ønsket 1 2
c. Blitt begrenset i type jobb eller aktiviteter 1 2
d. Hatt vanskeligheter med å utføre jobben eller andre aktiviteter (f eks det 
krevde større anstrengelse)
1 2
6. I løpet av de 4 siste ukene, i hvilken grad har plagene i beina kommet i veien for samvær med familie, venner, 
naboer eller grupper? (Sett ett kryss)
1 Ikke i det hele tatt 4 Ganske stor
2 Lett 5 Svær
3 Moderat
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7. Hvor mye smerter har du hatt i beina i løpet av de 4 siste ukene? (sett ett kryss)
1 Ingen 4 Moderat
2 Svært lite 5 Mye
3 Lite 6 Svært mye
8. Disse spørsmålene er om hvordan du føler deg, og om hvordan du har hatt det de siste 4 ukene som følge av
plagene i beina. For hvert spørsmål, kryss av for det svaret som passer best med hvordan du har følt deg. Hvor 
mye i løpet av de 4 siste ukene-
(Sett ett kryss på hver linje)
Hele 
tiden
Det 
meste av 
tiden
Ganske 
ofte
Av og til
Sjelden Aldri
a. har du vært bekymret for hvordan beina dine 
ser ut?
1 2 3 4 5 6
b. har du følt deg irritabel 1 2 3 4 5 6
c. har du følt at du har vært til byrde for familie 
eller venner?
1 2 3 4 5 6
d. har du vært bekymret for å skumpe borti ting? 1 2 3 4 5 6
e. har dine beins utseende påvirket ditt 
klesvalg ?
1 2 3 4 5 6
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b. EQ-5D 
Spørreskjema om helse
Opplysningene vil være til hjelp for å holde rede på hvordan du har det, og om hvordan du klarer å 
utføre dine vanlige aktiviteter.
Vis hvilke utsagn som passer best på din helsetilstand i dag ved å sette et kryss i en av
rutene utenfor hver av gruppene nedenfor.
Gange
Jeg har ingen problemer med å gå omkring. 
Jeg har litt problemer med å gå omkring. 
Jeg er sengeliggende. 
Personlig stell
Jeg har ingen problemer med personlig stell. 
Jeg har litt problemer med å vaske meg eller kle meg. 
Jeg er ute av stand til å vaske meg eller kle meg. 
Vanlige gjøremål (f.eks. arbeid, studier, husarbeid,
familie- eller fritidsaktiviteter).
Jeg har ingen problemer med å utføre mine vanlige gjøremål 
Jeg har litt problemer med å utføre mine vanlige gjøremål.    
Jeg er ute av stand til å utføre mine vanlige gjøremål. 
Smerte/ubehag
Jeg har verken smerte eller ubehag. 
Jeg har moderat smerte eller ubehag. 
Jeg har sterk smerte eller ubehag. 
Angst/depresjon
Jeg er verken engstelig eller deprimert. 
Jeg er noe engstelig eller deprimert. 
Jeg er svært engstelig eller deprimert. 
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